finerenone


( Last Updated : May 24, 2022)
Generic Name:
finerenone
Project Status:
Received
Therapeutic Area:
Chronic kidney disease
Manufacturer:
Bayer Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0737-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Bayer requests that finerenone 10 mg, and 20 mg be reimbursed as an adjunct to standard of care therapy to delay progression of kidney disease and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) and hospitalization for heart failure in adults with chronic kidney disease and type 2 diabetes. Standard of care includes: • an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), and • a sodium-glucose cotransporter-2 inhibitor (SGLT2i), unless contraindicated or not tolerated
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
N/A
Indications:
Finerenone is indicated to delay progression of kidney disease and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) and hospitalization for heart failure in adults with chronic kidney disease (CKD) and type 2 diabetes (T2D).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open22-Apr-22
Call for patient/clinician input closed17-Jun-22
Submission received20-May-22
Submission accepted